Eli Lilly company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
The company says it will share additional long-term findings and updated safety information for Kisunla, along with data tied to an Alzheimer’s blood test, at the 2026 Alzheimer’s Association International Conference.
THE APEX TIMES
THE APEX TIMES
The transfer of full mainland commercialization control of Verzenios to Innovent Biologics is reshaping expectations for Eli Lilly’s role in China oncology, while also adding to questions about valuation and regulatory exposure.
THE APEX TIMES
Eli Lilly shares rose about 2.8% in the afternoon after JPMorgan’s Chris Schott raised his price target to $1,400 from $1,300 and reiterated an Overweight rating, pointing to sustained demand for its weight-loss drugs and an expanded incretin pipeline.
THE APEX TIMES
Eli Lilly was among the day’s notable gainers even as the Nasdaq moved lower, with weakness also hitting memory and semiconductor equipment names such as Sandisk and Micron, according to market coverage published July 7, 2026.
THE APEX TIMES
A sharp selloff in drug shares renewed debate over whether Eli Lilly’s blockbuster weight-loss and diabetes franchise is losing steam. Jim Cramer argued the market’s narrative may be too pessimistic, pointing to a broader, crowded-trade unwind.
THE APEX TIMES
Lilly’s stock surged to a new peak after an IPO-linked biotech, Kailera Therapeutics, saw its weight-loss drug results described as underwhelming, according to market reporting.
THE APEX TIMES
After a rapid run-up that followed the company’s most recent earnings report, Eli Lilly’s valuation has drawn fresh scrutiny from market commentators asking how much more upside is realistically priced in.
THE APEX TIMES
An industry analyst says no peer group in pharma has been as far behind the No. 1 company as Lilly appears to be, pointing to expanding demand for its diabetes and obesity franchise and follow-on pipeline bets.
THE APEX TIMES
A recent market piece argues that even after a sharp run-up, long-horizon investors may still see upside from Eli Lilly’s growth engine, while acknowledging that the outcome depends heavily on the continued performance of its most important drugs.
